AJMC® in the Press, June 29, 2018

An article from Markets Insider, a branch of Business Insider, discussed a commentary published in the June issue of Evidence-Based Oncology^®, a sister publication of The American Journal of Managed Care^® (AJMC^®). The article, “Riding the Wave Through Chemo: Cancer Journey Leads to chemoWave App for Reporting PROs,” relays the personal story that led to the creation of chemoWave, a free app that enables cancer patients to record patient-outcomes and take greater control of their health during treatment.

The Grove City Review’s article on celebrity tributes for Cecile Richards as she steps down as president and chief executive officer of Planned Parenthood mentioned an AJMC^® article on Richards. In the article, “In Final Turn With Planned Parenthood, Cecile Richards Tells Obstetricians Women’s Healthcare ‘Has Long Way to Go,’” AJMC^® recounts Richards’ final speech, where she addressed the 2018 annual meeting of the American College of Obstetricians and Gynecologists and said she was optimistic because of the activism she sees among women and girls at the grassroot level.

Two articles from AJMC^® were included in the National Pharmaceutical Council’s CER Daily Newsfeed on Tuesday. The article, “Gottlieb Calls on Payers to Share Data to Aid Drug Innovation,” covered FDA Commissioner Scott Gottlieb’s, MD, remarks at the National Comprehensive Cancer Network Policy Summit, where he called for more data sharing and explained how the FDA is working to modernize the clinical trial process. The article, “Value-Based Payment Models Not Yet Reaching Full Potential, Study Says,” covered a study that found the penetration of value-based payment models is not yet enough to generate cost savings and is also not affecting clinical quality outcomes at the market level.

The Biologics Prescribers Collaborative, a project of the Alliance for Patient Access, highlighted an article from The Center for Biosimilars^®, a sister publication of AJMC^®, in its Wednesday newsletter. The article, “Azar Testifies on the Need to Reduce Drugs’ List Prices, Provider Group Raises Concerns,” reported on Azar’s testimony before the Senate’s Committee on Health, Education, Labor, and Pensions on the Trump administration’s blueprint to lower drug prices.